An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 29, 2026 - P1/2 | N=21 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|